| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PFE | Common Stock | Tax liability | $2,627,306 | -61,994 | -15% | $42.38 | 352,477 | 22 Feb 2023 | Direct | F1 |
| holding | PFE | Common Stock | 4,282 | 22 Feb 2023 | By Rule 16b-3 Plan |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PFE | Stock Appreciation Rights | Award | $0 | +413,280 | $0.000000 | 413,280 | 23 Feb 2023 | Common Stock | 413,280 | $42.30 | Direct | F2 | |
| transaction | PFE | Stock Appreciation Rights | Award | $0 | +359,681 | $0.000000 | 359,681 | 23 Feb 2023 | Common Stock | 359,681 | $42.30 | Direct | F3 |
| Id | Content |
|---|---|
| F1 | The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the settlement of stock units from previously exercised stock appreciation rights (including dividend equivalents thereon). |
| F2 | The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. |
| F3 | The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. |